IDEAYA Biosciences (NASDAQ:IDYA) Announces Earnings Results

Posted by Francis Steltz on Aug 4th, 2026

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) released its earnings results on Tuesday. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.16), Zacks reports. The business’s quarterly revenue was up 8800.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.88) earnings per share.

IDEAYA Biosciences Price Performance

IDEAYA Biosciences stock traded down $0.20 during mid-day trading on Tuesday, reaching $35.20. 149,311 shares of the company traded hands, compared to its average volume of 1,104,149. The firm’s fifty day moving average is $33.82 and its two-hundred day moving average is $32.65. IDEAYA Biosciences has a fifty-two week low of $22.09 and a fifty-two week high of $40.58. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of -22.00 and a beta of -0.10.

Insider Buying and Selling

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the sale, the chief accounting officer owned 26,466 shares in the company, valued at $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of institutional investors have recently modified their holdings of the stock. Daiwa Securities Group Inc. grew its stake in shares of IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares during the period. Parallel Advisors LLC grew its position in shares of IDEAYA Biosciences by 23.4% during the 4th quarter. Parallel Advisors LLC now owns 3,847 shares of the company’s stock valued at $133,000 after acquiring an additional 730 shares during the period. Osaic Holdings Inc. increased its stake in shares of IDEAYA Biosciences by 59.1% in the 2nd quarter. Osaic Holdings Inc. now owns 7,443 shares of the company’s stock valued at $148,000 after purchasing an additional 2,764 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in IDEAYA Biosciences by 677.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,538 shares of the company’s stock worth $200,000 after purchasing an additional 8,311 shares during the period. Finally, Xponance LLC purchased a new position in IDEAYA Biosciences during the fourth quarter worth approximately $218,000. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on IDYA shares. Wells Fargo & Company increased their price target on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. Wedbush restated an “outperform” rating and issued a $58.00 price target on shares of IDEAYA Biosciences in a research report on Friday, June 12th. Citigroup restated a “market outperform” rating on shares of IDEAYA Biosciences in a research report on Tuesday, June 2nd. Truist Financial reduced their target price on IDEAYA Biosciences from $65.00 to $63.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Finally, Wall Street Zen upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.25.

View Our Latest Analysis on IDYA

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.